Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026)
Intellia Therapeutics (NTLA) reported Interest & Investment Income of $5.2 million for Q1 2026, down 39.5% year-over-year from $8.6 million in Q1 2025, and down 19.63% quarter-over-quarter from $6.5 million in Q4 2025.
Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 11 years of Interest & Investment Income data on file, last reported at $5.2 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $5.2 million, down 39.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.8 million (down 41.07% YoY), and the FY2025 annual result was $29.2 million, down 38.93% from the prior year.
- Interest & Investment Income declined to $5.2 million in Q1 2026 per NTLA's latest filing, from $6.5 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $12.7 million in Q3 2023 and troughed at $540000.0 in Q1 2022.
- A 5-year average of $8.3 million and a median of $8.6 million in 2025 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income jumped 2118.52% in 2023, then sank 44.61% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $5.4 million in 2022, then surged by 132.7% to $12.5 million in 2023, then declined by 14.67% to $10.6 million in 2024, then slumped by 39.08% to $6.5 million in 2025, then dropped by 19.63% to $5.2 million in 2026.
- Business Quant data shows NTLA's Interest & Investment Income at $5.2 million in Q1 2026, $6.5 million in Q4 2025, and $6.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 6.48 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 7.40 Mn |
| Mar 31, 2025 | 8.60 Mn |
| Dec 31, 2024 | 10.63 Mn |
| Sep 30, 2024 | 12.12 Mn |
| Jun 30, 2024 | 12.42 Mn |
| Mar 31, 2024 | 12.63 Mn |
| Dec 31, 2023 | 12.46 Mn |
| Sep 30, 2023 | 12.74 Mn |
| Jun 30, 2023 | 12.65 Mn |
| Mar 31, 2023 | 11.98 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Sep 30, 2022 | 1.95 Mn |
| Jun 30, 2022 | 703,000.00 |
| Mar 31, 2022 | 540,000.00 |
| Dec 31, 2021 | 503,000.00 |
| Sep 30, 2021 | 349,000.00 |
| Jun 30, 2021 | 211,000.00 |